return equiti ttm
third-quart earn continu ultomiri convers neurolog
growth soliri execut remain under-valued
market open wednesday octob alexion report third-quart
financi result provid corpor updat compani total revenu
third quarter billion year-over-year sale mainli driven
volum growth soliri gmg nmosd volum growth strensiq pnh
patient convers ultomiri result price tailwind compani increas
full-year guidanc reflect on-going growth gmg ultomiri convers
nmosd launch total revenu guidanc increas billion
billion billion billion indic year-over-year growth
guidanc midpoint non-gaap ep guidanc increas
reflect increas year-over-year growth midpoint guidanc
summari full year updat guidanc summar exhibit base
updat guidanc adjust model increas fourth quarter
soliri revenu million million decreas sg expens
million million result increas ep dilut
estim total revenu billion billion complement
franchis non-gaap ep continu believ complement
franchis durabl growth prospect remain under-valued addit detail see
initi despit ip competit overhang believ complement franchis
durabl remain under-valued initi outperform
octob pnh patient success convert soliri
ultomiri compani remain track convert patient
moreov patient germani launch juli patient
japan launch septemb convert ultomiri exceed launch
trajectori unit state increas ex-u convers rate attribut
concentr prescrib base insight launch ultomiri pnh
launch on-going austria denmark finland compani continu
work toward addit eu launch regard reach convers threshold
indic unit state pend approv compani guid late
ahu late gmg nmosd convers guidanc
europ japan pnh earli late ahu respect
earli gmg respect earli nmosd respect
base ultomiri clinic profil sustain price reduc infus near-term
increas deliveri option manag remain confid patient convert
maintain treatment ultomiri potenti soliri biosimilar launch
global biopharmaceut compani focus discoveri develop
commerci therapi rare ultra-rar diseas
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
alexion continu diversifi pipelin expans new indic busi develop deal result
develop program across asset pend transact close/opt exercis across late-stag asset compani
potenti address differ indic span ultra rare rare diseas address sizabl patient
popul lastli compani plan leverag expand neurolog franchis gmg nmosd treat
peopl unit state soliri patient quarter-over-quart track largest patient
franchis unit state year-end potenti launch next two year expect catalyst-rich
compani exhibit summar catalyst expect year-end
rate share alexion outperform central thesi belief alexion remain leader atyp hemolyt
urem syndrom ahu paroxysm nocturn hemoglobinuria pnh ultomiri transition/market expertis
former compani alreadi plan convert view achiev supplement
continu launch potenti market expans gener myesthenia gravi gmg neuromyel optica spectrum
disord nmosd launch begin unit state second half view best-in-class data
risk invest primarili competit relat compani complement franchis alexion involv on-going ipr
relat soliri patent unit state well recent neg patent extens decis eu
william blair affili market maker secur inc
william blair affili expect receiv intend seek compens invest bank servic alexion
pharmaceut inc affili within next three month
offic employe william blair affili research analyst may financi interest secur alexion
report avail electron form regist user via doc http //williamblairlibrari bluematrix com
pleas contact us consult williamblair com/research-and-insights/equity-research/coverag aspx disclosur
raju prasad attest view express research report accur reflect his/her person view
secur compani cover report part his/her compens relat directli indirectli
specif recommend view express him/her report seek updat research appropri
certain period industri report major report publish irregular interv deem appropri research
xion pha rm ce ut ica ls inc ra ing hist ori
power bluematrix
op outperform market market perform perform nr rate initi coverag drop coverag
current rate distribut octob
addit inform avail upon request
percentag compani rate categori invest bank client defin compani william blair
receiv compens invest bank servic within past month
compens research analyst base varieti factor includ perform stock recommend
contribut firm depart includ asset manag corpor financ institut sale retail brokerag firm
profit competit factor
